Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Viatris Inc — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $34.36 (market cap $1.96B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 10.2× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Viatris Inc pays a 2.75% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and Viatris Inc for 57 Days on average.
| SOXS | VTRS | |
|---|---|---|
Market Cap | $1.96B | $20.03B |
Volume | 113,512,541 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $18.27 |
52-Week Low | $29.62 | $9.74 |
Typical Hold Time | 11 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $34.39, up 12.22% today, reflecting its inverse leveraged exposure to semiconductor stocks. The technical picture is bearish overall, with moving averages signaling a downtrend. Recent news highlights the fund's volatility and tactical use during semiconductor sector pullbacks, driven by factors like AI demand fluctuations and competitive pressures on chipmakers.
The outlook for SOXS remains highly speculative, suitable only for short-term traders betting against semiconductors. Key risks include the fund's decay from daily rebalancing, reliance on semiconductor volatility, and potential for rapid losses if the sector rallies. Investors should avoid long-term holdings due to structural erosion and elevated volatility.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
